Structure-activity studies leading to (-)1-(benzofuran-2-yl)-2-propylaminopentane, ((-)BPAP), a highly potent, selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain.

@article{Yoneda2001StructureactivitySL,
  title={Structure-activity studies leading to (-)1-(benzofuran-2-yl)-2-propylaminopentane, ((-)BPAP), a highly potent, selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain.},
  author={Fumio. Yoneda and Tetsushi Moto and Masatoshi Sakae and Hironori Ohde and Bertha Knoll and Ildikó Miklya and Joseph Knoll},
  journal={Bioorganic \& medicinal chemistry},
  year={2001},
  volume={9 5},
  pages={
          1197-212
        }
}
Transporter-mediated actions of R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane.
The fate of (−)1-(benzofuran-2-yl)-2-propylaminopentane · HCl, (−)-BPAP, in rats, a potent enhancer of the impulse-evoked release of catecholamines and serotonin in the brain
TLDR
Radioactivity was well absorbed and penetrated the brain, its elimination was fast and enterohepatic circulation was observed in rats, and more than 90% of the substance was recovered in the excreta during 72 hours.
The use of the synthetic enhancer substances (-)-deprenyl and (-)-BPAP in major depression.
  • P. Gaszner, I. Miklya
  • Biology, Chemistry
    Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology
  • 2004
TLDR
The evaluation of the special pharmacological profile of the synthetic mesencephalic enhancer substance, especially the high potency and the unusual safety and tolerability of (-)-BPAP provide hope that this compound may in the future significantly improve the effectiveness of drug therapy in major depression and its combination with uptake inhibitors may substantially diminish the number of therapy resistant cases.
...
...

References

SHOWING 1-10 OF 25 REFERENCES
The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.
TLDR
Early deprenyl therapy delays the requirement for antiparkinsonian medication, possibly by slowing progression of the disease.
Monoamine oxidase B inhibitor selegiline protects young and aged rat peripheral sympathetic neurons against 6-hydroxydopamine-induced neurotoxicity
TLDR
The findings showed that 6-OHDA caused a reduction of TH immunoreactivity and catecholamine histofluorescence in neuronal somata, as well as a decrease in the number and length of adrenergic nerve fibers in the submandibular gland.
A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.
TLDR
In patients with moderately severe impairment from Alzheimer's disease, treatment with selegiline or alpha-tocopherol slows the progression of disease.
Deprenyl (selegiline): the history of its development and pharmacological action
  • J. Knoll
  • Biology, Chemistry
    Acta neurologica Scandinavica. Supplementum
  • 1983
TLDR
Deprenyl inhibits MAO‐B selectively in different animal species and in man and is able to block MAO-B activity in the brain selectively in vivo in four species with s.c. administration.
Rescue of dying neurons: A new action for deprenyl in MPTP parkinsonism
TLDR
Research shows that deprenyl can increase SNc neuronal survival by a mechanism that is independent of the blockade of MPTP's conversion to MPP+ and may be responsible for slowing the progressioon of PD.
Effect of deprenyl on the progression of disability in early Parkinson's disease.
TLDR
It is concluded from these preliminary results that the use of deprenyl (10 mg per day) delays the onset of disability associated with early, otherwise untreated cases of Parkinson's disease.
...
...